Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives

Has This Poison Pill Lost Its Bite?

Inside Wall Street


Shared Medical Systems is one of the few computer-information companies whose shares haven't declined recently. The stock has stayed close to its high of 21, even though management just installed a shareholder-rights plan that makes it expensive for any unwelcome group to acquire the company. In early January, Shared Medical Systems traded at 13.

But an insider says that several directors have changed their minds since the poison pill took effect on May 1, and they may now welcome an offer. One investor group is shopping the company, a leading provider of computer-based information systems to hospitals, clinics, and physicians. The group led by David J. Greene, a New York investment firm, has a 10.6% stake. Greene thinks the stock is undervalued and believes the only way to boost the shares is to sell the company. Some takeover pros value Shared Medical Systems at more than $30 a share.

One 13D Research analyst says the company has "an extremely strong franchise that's recession-resistant" and a revenue base roughly two times that of its closest competitor. After a slowdown in 1989, earnings picked up last year, rising to $1.01 a share from 79~. The analyst expects earnings of $1.20 this year.

So far, Greene won't talk about the search. But some big investors bet it will come up with a buyer soon. Shared Medical declined comment.GENE G. MARCIAL

blog comments powered by Disqus